Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 8;18(11):1270–1276. doi: 10.1038/s41589-022-01140-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a, Intact scFv-based ReconnAbs (orange) show potent neutralization of SARS-CoV-2 VOCs. Inhibition is markedly reduced upon TEV cleavage (teal). Pseudoviral IC₅₀ for ReconnAbs against a range of SARS-CoV-2 VOCs with and without TEV cleavage. IC₅₀ values shown are the average of two independent experiments. b–d, A bi-functional IgG ReconnAb shows potent neutralization of SARS-CoV-2 VOCs. b, A schematic representation of the CV10-2449–ACE2 CrossMAb indicates linkage of ACE2 and bi-functional Fab arms. c, Pseudoviral IC₅₀ for CV10-2449–ACE2 CrossMAb against a range of SARS-CoV-2 VOCs with and without TEV cleavage. IC₅₀ values shown are the average of two independent experiments. The red dotted line indicates the average neutralization of Fc-ACE2 as in Supplementary Fig. 12. d, Intact IgG CrossMAb ReconnAbs (orange) show neutralization of SARS-CoV-2 BA.2. Inhibition is markedly reduced upon TEV cleavage (teal). The CrossMAb IgG ReconnAb neutralizes the BA.2 Omicron variant at ~50 pM NT₅₀. Error bars denote standard deviation. A representative plot is shown.